A Synthetic Interaction Screen Identifies Factors Selectively Required for Proliferation and TERT Transcription in p53-Deficient Human Cancer Cells

PLoS Genetics

Volumn 8, Issue 12, 2012, Pages

  Xie, Li ^a   Gazin, Claude ^a,b,c   Park, Sung Mi ^a   Zhu, Lihua J ^a   Debily, Marie anne ^b,d   Kittler, Ellen L W ^a   Zapp, Maria L ^a   Lapointe, David ^a   Gobeil, Stephane ^a,e   Virbasius, Ching Man ^a   Green, Michael R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Parc Scientifique de Luminy   (France)

^c INSERM   (France)

^d UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^e LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; PROTEIN P53; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ER81;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENETICS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EMBRYO; ENZYME ACTIVE SITE; GENE INTERACTION; GENETIC SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSCRIPTION INITIATION SITE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; TELOMERASE; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872022032     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003151     Document Type: Article

References (65)

1. Reinhardt HC, Schumacher B, (2012) The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 28: 128-136.
2. Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P, (2010) Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 22: 64-69.
3. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, et al. (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42-48.
4. Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, et al. (2002) p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13: 1108-1115.
5. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, et al. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157.
6. Essmann F, Schulze-Osthoff K, (2012) Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol 165: 328-344.
7. Martins CP, Brown-Swigart L, Evan GI, (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334.
8. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
9. Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
10. Senzer N, Nemunaitis J, (2009) A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther 11: 54-61.
11. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP, (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873.
12. Selivanova G, Wiman KG, (2007) Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26: 2243-2254.
13. Cheok CF, Verma CS, Baselga J, Lane DP, (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
14. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH, (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278: 1064-1068.
15. Luo J, Solimini NL, Elledge SJ, (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
16. Weinstein IB, Joe A, (2008) Oncogene addiction. Cancer Res 68: 3077-3080; discussion 3080.
17. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
18. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
19. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115.
20. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
21. Silva JM, Li MZ, Chang K, Ge W, Golding MC, et al. (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37: 1281-1288.
22. Weinberg RA (2006) Biology of Cancer: Garland Science.
23. Shaulian E, Zauberman A, Ginsberg D, Oren M, (1992) Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 12: 5581-5592.
24. Cimprich KA, Cortez D, (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9: 616-627.
25. Oh S, Shin S, Janknecht R, (2012) ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta 1826: 1-12.
26. Goueli BS, Janknecht R, (2004) Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 24: 25-35.
27. Belgiovine C, Chiodi I, Mondello C, (2008) Telomerase: cellular immortalization and neoplastic transformation. Multiple functions of a multifaceted complex. Cytogenet Genome Res 122: 255-262.
28. Won J, Kim M, Kim N, Ahn JH, Lee WG, et al. (2006) Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol 2: 369-374.
29. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, et al. (2011) A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 18: 721-727.
30. Cortez D, Glick G, Elledge SJ, (2004) Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci U S A 101: 10078-10083.
31. Kim ST, Lim DS, Canman CE, Kastan MB, (1999) Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274: 37538-37543.
32. O'Neill T, Dwyer AJ, Ziv Y, Chan DW, Lees-Miller SP, et al. (2000) Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem 275: 22719-22727.
33. Choi JH, Lindsey-Boltz LA, Kemp M, Mason AC, Wold MS, et al. (2010) Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling. Proc Natl Acad Sci U S A 107: 13660-13665.
34. Cortez D, Guntuku S, Qin J, Elledge SJ, (2001) ATR and ATRIP: partners in checkpoint signaling. Science 294: 1713-1716.
35. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) GammaH2AX and cancer. Nat Rev Cancer 8: 957-967.
36. Kyo S, Takakura M, Fujiwara T, Inoue M, (2008) Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 99: 1528-1538.
37. Koutsodontis G, Tentes I, Papakosta P, Moustakas A, Kardassis D, (2001) Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. J Biol Chem 276: 29116-29125.
38. Innocente SA, Lee JM, (2005) p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett 579: 1001-1007.
39. Esteve PO, Chin HG, Pradhan S, (2007) Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282: 2615-2625.
40. Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Korner S, et al. (2011) Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A 108: 14240-14245.
41. Cai BH, Hsu PC, Hsin IL, Chao CF, Lu MH, et al. (2012) p53 Acts as a Co-Repressor to Regulate Keratin 14 Expression during Epidermal Cell Differentiation. PLoS ONE 7: e41742 doi: 10.1371/journal.pone.0041742.
42. Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL, (2001) ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A 98: 9092-9097.
43. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, et al. (2011) Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7: 428-430.
44. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G, (2005) RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res 65: 2872-2881.
45. Murga M, Bunting S, Montana MF, Soria R, Mulero F, et al. (2009) A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 41: 891-898.
46. Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL, (2009) A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS ONE 4: e4798 doi:10.1371/journal.pone.0004798.
47. Krastev DB, Slabicki M, Paszkowski-Rogacz M, Hubner NC, Junqueira M, et al. (2011) A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. Nat Cell Biol 13: 809-818.
48. Bassik MC, Lebbink RJ, Churchman LS, Ingolia NT, Patena W, et al. (2009) Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat Methods 6: 443-445.
49. Prieur A, Besnard E, Babled A, Lemaitre JM, (2011) p53 and p16(INK4A) independent induction of senescence by chromatin-dependent alteration of S-phase progression. Nat Commun 2: 473.
50. Cao Y, Li H, Deb S, Liu JP, (2002) TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 21: 3130-3138.
51. Bojovic B, Crowe DL, (2011) Resistance to telomerase inhibition by human squamous cell carcinoma cell lines. Int J Oncol 38: 1175-1181.
52. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, et al. (2008) TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet 4: e10 doi:10.1371/journal.pgen.0040010.
53. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, et al. (2009) Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460: 66-72.
54. Smith LL, Coller HA, Roberts JM, (2003) Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 5: 474-479.
55. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, et al. (2002) Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22: 2111-2123.
56. Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, et al. (2009) An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461: 230-235.
57. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
58. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser V 57: 289-300.
59. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
60. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
61. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92: 9363-9367.
62. Lindsey-Boltz LA, Sancar A, (2011) Tethering DNA damage checkpoint mediator proteins topoisomerase IIbeta-binding protein 1 (TopBP1) and Claspin to DNA activates ataxia-telangiectasia mutated and RAD3-related (ATR) phosphorylation of checkpoint kinase 1 (Chk1). J Biol Chem 286: 19229-19236.
63. Raha T, Cheng SW, Green MR, (2005) HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol 3: e44 doi:10.1371/journal.pbio.0030044.
64. Zeng PY, Vakoc CR, Chen ZC, Blobel GA, Berger SL, (2006) In vivo dual cross-linking for identification of indirect DNA-associated proteins by chromatin immunoprecipitation. Biotechniques 41: 694, 696, 698.
65. Mirzoeva OK, Petrini JH, (2001) DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol Cell Biol 21: 281-288.